New indication for Inegy
Inegy (simvastin, ezetimibe; Merck Sharp & Dohme) is now indicated to reduce the risk of cardiovascular events in patients with coronary heart disease and a history of acute coronary syndrome, either previously treated with a statin or not. Further changes to the summary of product characteristics reflect this addition.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200796
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com